Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain

NCT02920528 ↗

Phase 3 Completed 106 enrolled Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center United States Air Force Research Laboratory · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a prospective, randomized controlled trial which will be conducted to determine whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with chronic pain syndrome presenting to the emergency department with exacerbation of their chronic pain. The investigators also aim to determine whether use of SDDK can reduce the amount of subsequent opioid pain medications required for adequate pain relief in this population.

Timeline

Start: 2017-05-01
Primary completion: 2018-06-22
Completion: 2019-09-01

Outcome

Met primary endpoint

paper Primary endpoint analysis found that 25 of 30 (83%) improved with 0.5 mg/kg ketamine PMID 30901130 ↗

paper 13 of 32 (41%) with placebo (p = 0.001). PMID 30901130 ↗

Publications

Lumanauw DD, Youn S, Horeczko T, Yadav K, Tanen DA. Subdissociative-dose Ketamine Is Effective for Treating Acute Exacerbations of Chronic Pain. Acad Emerg Med. 2019 Sep;26(9):1044-1051. doi: 10.1111/acem.13755. Epub 2019 Apr 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	0.25 mg/kg	Intravenous
Subject	Ketamine	Small molecule	0.5 mg/kg	Intravenous